New York Life Investment Management’s Meridian Bioscience Inc VIVO Stock Holding History

New York Life Investment Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-117,891	Closed	-$3.92M	–	1457
2022 Q4	$3.92M	Sell	117,891 -22,395	-16%	-$721K	0.04%	370
2022 Q3	$4.42M	Buy	140,286 +122,322	+681%	+$3.96M	0.05%	338
2022 Q2	$546K	Buy	+17,964	New	+$486K	0.01%	689

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

New York Life Investment Management's VIVO Position: Q1 2023 in Review

New York Life Investment Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 117,891 shares — an estimated $3.92M sold.

New York Life Investment Management first reported a position in VIVO in Q2 2022 and held it in 3 quarters. The position peaked at $4.42M in Q3 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

New York Life Investment Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
New York Life Investment Management sold 117,891 Meridian Bioscience Inc shares in Q1 2023, an estimated $3.92M.
New York Life Investment Management first reported a position in Meridian Bioscience Inc in Q2 2022 and held it in 3 quarters.
New York Life Investment Management's Meridian Bioscience Inc position peaked at $4.42M in Q3 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.